Publication Author: Ezekowitz JA
Filter by Author:
The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial.
Fioretti F, Zannad F, Barash I, Corda S, Ezekowitz JA, Lam CSP, Mentz RJ, O'Connor CM, Bayh I, Xing A, Butler J; VICTOR Study Group.
Machine learning model for predicting improvement in left ventricular systolic function in patients with heart failure and reduced ejection fraction.
Sepehrvand N, Gilbert C, Chunta A, Youngson E, Ezekowitz JA, Fine NM, Howlett JG, McAlister FA, Miller RJH.
Outcomes and Patterns Related to Magnesium in Acute Heart Failure: A Population-Based Study.
Margaryan R, Islam S, Dover D, McAlister FA, Kaul P, Ezekowitz JA.
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N; Conference Participants.
Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N; Conference Participants.
After cardioversion in AF, continued caffeinated coffee consumption vs. abstinence reduced AF or atrial flutter recurrence at 6 mo.
Agarwal A, Ezekowitz J; ACP Journal Club Editorial Team at McMaster University.
Diagnosis of Cardiac Amyloidosis on Echocardiography Using Artificial Intelligence.
Ioannou A, Khouri MG, Kitai T, Vemulapalli S, Hung CL, Lim SC, Frost M, Tee WW, Mansell J, Sheikh A, Venneri L, Razvi Y, Porcari A, Martinez-Naharro A, Rauf MU, Lachmann H, Hawkins PN, Wechelakar A, Moody W, Bandera F, Ezekowitz JA, Lam CSP, Solomon SD, Gillmore JD, Fontana M.
Factors associated with the development of severe mitral regurgitation in patients with heart failure.
Ahmed F, Youngson E, Sasikumar A, Ezekowitz JA, Fine N, McAlister FA, Howlett JG, Miller RJH.
Standardized Reporting in Heart Failure Noninvasive Remote Monitoring Trials: Interventions to Catalyze Data Into Action.
Shalowitz EL, Jhund P, Psotka MA, Sharma A, Dimond M, Martyn T, Cowie M, Moayedi Y, Hawkins NM, Ezekowitz J, Amir O, Volterrani M, Fiuzat M, O'Connor C, Kao DP; Heart Failure Collaboratory and Canadian Heart Failure Society.
Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry
McDonald MA, Kok M, Ducharme A, Ezekowitz JA, Howlett J, Rojas-Fernandez C, Udell JA
Corrigendum to Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%): [Canadian Journal of Cardiology. Volume 41, Issue 10, October 2025, Pages 1857-1874. doi:10.1016/j.cjca.2025.07.027].
Virani S, Zieroth S, Aleksova N, Anderson K, Clarke B, Ducharme A, Ezekowitz JA, Foroutan F, Giannetti N, Jain R, Lee D, Lepage S, Lyons K, McDonald M, McGuinty C, Mielniczuk L, O'Meara E, Poon S, Siatecki K, Swiggum E, Toma M, Turgeon RD, Bains M, Davis MK, De S, Fine N, Heshka J, Keen S, King A, Lavoie A, Mak S, McCleary L, Outbih O, Pike R, Sharma A, van Spall HGC, Ching Yip AM.
Dapagliflozin in Acute Cardiovascular Conditions: Insights From the DEFENDER Trial.
Tavares CAM, Azevedo LCP, Guimarães PO, Rea-Neto Á, David-João PG, Campos NS, Amendola CP, Kozesinski-Nakatani AC, Filiponi TC, Almeida GMB, Bergo RR, Lobo SM, Tognon AP, Tavares MS, Silveira FS, Dracoulakis MDA, Biondi RS, Monfardini F, Nieri J, Madrini V Jr, Serpa-Neto A, Bacal F, Lemos PA, Berwanger O, Ezekowitz JA, Zampieri FG; DEFENDER Investigators.
An Analysis of Patient Recovery and Opinions on Driving Post-Transcatheter Aortic Valve Insertion (TAVI): the TAVI-D Study.
Jarvis CR, Gouda P, Ezekowitz J, Smith H, Tyrrell B, Welsh RC
Re”FINE”ing Our Understanding of Finerenone in Heart Failure Across the Spectrum of Cardio-Kidney-Metabolic Risk.
Chatur S, Ezekowitz J.
The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.
Almufleh A, Brahmbhatt DH, Billia F, Clarke B, Didi A, Nair P, Toma M, Anderson K, Mielniczuk L, Van Diepen S, Boulet J, McDonald M, Moghaddam N, Aziz H, Davis M, Zieroth S, Ezekowitz J.
The Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) Trial-IMAGE HF Project 1A
Mielniczuk LM, O'Meara E, Wiefels C, Chen L, Garrard L, White J, deKemp RA, Di Carli MF, Larose E, Paterson DI, Ezekowitz J, Kandolin RM, Wright G, Campisi R, Laine MK, Connelly K, Rajda M, Vitola JV, Lepage S, Hartikainen J, Chow B, Tavoosi A, Knuuti J, Wells GA, Beanlands RSB; IMAGE HF Investigators.
Testing for Coronary Artery Disease in Patients Newly Diagnosed with Heart Failure in Alberta, Canada.
Munir A, Chu LM, Kaul P, Ezekowitz JA, McAlister FA
Testing for Coronary Artery Disease in Patients Newly Diagnosed with Heart Failure in Alberta, Canada.
Munir A, Chu LM, Kaul P, Ezekowitz JA, McAlister FA
Diet and Clinical Outcomes in a Heart Failure Population.
Joseph P, Dehghan M, Ezekowitz JA, Miller V, Lanas F, AlHabib KF, Gomez-Mesa JE, ElSayed A, Lopez-Jaramillo P, Avezum A Jr, Bayes-Genis A, Ertl G, Lund LH, Karaye K, Maggioni A, Diaz ML, Balasubramanian K, Grinvalds A, Roy A, Pogosova N, Temizhan A, Leong D, McCready T, Yusuf S; G-CHF (Global Congestive Heart Failure) Registry Investigators.
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure.
Udelson JE, Bělohlávek J, Dukát A, Ezekowitz J, Goland S, Merkely B, O'Meara E, Petrie MC, Ponikowski P, Senni M, Tokmakova M, Vardeny O, Claggett B, Moore E, Savard M, McKellar H, Surks HK, Solomon SD, McMurray JJV.
